Intracranial Efficacy
intracranial disease
At the data cutoff, 51 patients (63.8%) in the gefitinib plus chemotherapy group and 65 patients (80.2%) in the gefitinib group had confirmed intracranial disease progression. The median intracranial PFS was 15.6 months (95% CI, 14.3-16.9 months) in the gefitinib plus chemotherapy group vs 9.1 months (95% CI, 8.0-10.2 months) in the gefitinib group (HR, 0.36; 95% CI, 0.25-0.53; 